17-OH Progesterone Test Price & Details at Chughtai Lab

17-OH Progesterone at Chughtai Lab

The 17-OH Progesterone (17-hydroxyprogesterone) test is a highly specialized clinical chemistry and endocrinology investigation utilized to measure the concentration of 17-OHP in the blood. This steroid hormone is an essential intermediate precursor in the biosynthetic pathway that converts cholesterol into cortisol. The synthesis of this hormone occurs primarily within the adrenal cortex—specifically in the zona fasciculata—and to a lesser extent within the gonads (ovaries and testes). Under normal physiological conditions, the enzyme 21-hydroxylase converts 17-OH progesterone into 11-deoxycortisol, which is subsequently metabolized into cortisol. When there is a genetic deficiency or impairment of this enzyme, the pathway is blocked, leading to an accumulation of 17-OH progesterone in the bloodstream. This clinical evaluation is of paramount diagnostic value in identifying congenital adrenal hyperplasia (CAH), monitoring therapeutic efficacy in affected patients, and investigating endocrine disorders related to hyperandrogenism.

At Chughtai Lab, one of Pakistan’s premier diagnostic networks, this investigation is performed using state-of-the-art automated immunoassay platforms. By utilizing advanced chemiluminescence immunoassay (CLIA) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) technologies, Chughtai Lab ensures clinical accuracy, high sensitivity, and specificity for patients across Lahore, Karachi, Islamabad, and other major cities. Evaluating 17-OH progesterone levels is critical because excessive accumulation of this precursor hormone shunts the steroidogenesis pathway toward the production of adrenal androgens, such as testosterone and androstenedione. This biochemical shift can result in profound physiological consequences, including ambiguous genitalia in female newborns, rapid somatic growth, premature epiphyseal fusion, and virilization. Consequently, this test serves as a cornerstone diagnostic tool in pediatric endocrinology, reproductive medicine, and adult endocrinology.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest degree of clinical accuracy and to minimize the impact of physiological variables, patients must adhere to specific preparation guidelines prior to undergoing the 17-OH Progesterone test at Chughtai Lab:

• Diurnal Variation Considerations: Levels of 17-OH progesterone exhibit a distinct diurnal rhythm, peaking in the early morning hours alongside cortisol. It is highly recommended that the blood sample be collected between 6:00 AM and 8:00 AM.
• Menstrual Cycle Timing: For adult and adolescent females, the timing of sample collection is critical. The test should ideally be performed during the early follicular phase of the menstrual cycle (typically days 2 to 5), as progesterone and 17-OH progesterone levels naturally rise during the luteal phase, which can lead to false-positive or difficult-to-interpret results.
• Fasting Guidelines: While absolute fasting is not always mandatory, a fasting period of 8 to 12 hours is preferred to minimize lipemia in the serum sample, which can interfere with certain immunoassay methodologies. Only plain water is permitted during this period.
• Medication Disclosure: Patients must inform their healthcare provider and the laboratory staff of all medications currently being taken, particularly glucocorticoids (such as hydrocortisone, prednisone, or dexamethasone), oral contraceptives, progesterone supplements, or any other hormonal therapies, as these can significantly suppress or alter endogenous hormone levels.
• Stress Management: Physical and emotional stress can stimulate the hypothalamic-pituitary-adrenal (HPA) axis, leading to transient elevations in ACTH and adrenal steroids. Patients should remain calm and rest quietly for 15 to 30 minutes before the blood draw.

During the Procedure

The collection of the blood specimen for the 17-OH Progesterone test at Chughtai Lab follows strict clinical protocols to maintain sample integrity and patient safety:

• Patient Positioning: The patient is comfortably seated or placed in a recumbent position. The phlebotomist will verify the patient’s identity using at least two unique identifiers (e.g., name and registration number) in accordance with international patient safety goals.
• Site Selection and Preparation: A suitable vein, typically the median cubital vein in the antecubital fossa of the arm, is selected. The skin over the venipuncture site is thoroughly cleansed with a 70% isopropyl alcohol swab using a circular motion from the center outward and allowed to air dry completely to prevent hemolysis.
• Venipuncture and Sample Collection: A sterile, single-use needle attached to a vacuum collection system is inserted into the vein. The blood is collected into a serum separator tube (SST, gold-top) or a plain red-top tube. The tube is filled to its designated capacity to ensure the correct blood-to-additive ratio.
• Post-Phlebotomy Care: Once the blood collection is complete, the needle is gently withdrawn, and immediate, direct pressure is applied to the puncture site with a sterile gauze pad to promote hemostasis and prevent hematoma formation. A hypoallergenic adhesive bandage is then applied.
• Sample Processing: The collected specimen is allowed to clot naturally in an upright position for 30 minutes before being centrifuged at the standardized speed and duration to separate the serum from the cellular components. The isolated serum is then transferred to the analytical department or preserved at the appropriate temperature if transport is required.

When is a 17-OH Progesterone Test Performed?

Screening for Congenital Adrenal Hyperplasia (CAH) in Newborns

The primary clinical indication for ordering a 17-OH Progesterone test is the screening and diagnosis of Congenital Adrenal Hyperplasia (CAH) in neonates. CAH is an autosomal recessive disorder characterized by a deficiency in one of the enzymes required for cortisol synthesis. Approximately 90% to 95% of CAH cases are caused by mutations in the CYP21A2 gene, which encodes the 21-hydroxylase enzyme. In newborns, especially those presenting with poor feeding, vomiting, dehydration, hypotension, and electrolyte imbalances (such as hyponatremia and hyperkalemia), this test is critical to detect the classic salt-wasting form of CAH. Early detection through this biochemical marker is life-saving, as severe salt-wasting crises can lead to hypovolemic shock, cardiac arrhythmias, and neonatal mortality if left untreated.

Investigating Ambiguous Genitalia in Infants

When a female infant is born with atypical or ambiguous external genitalia—such as clitoromegaly, fused labia, or a urogenital sinus—physicians immediately request a 17-OH Progesterone test. Due to the enzymatic block in 21-hydroxylase deficiency, the excess accumulation of 17-OHP is shunted into the androgenic pathway, leading to high levels of testosterone in utero. This exposure to high androgen levels causes virilization of the female fetus, while the internal reproductive organs (uterus and fallopian tubes) develop normally. Measuring 17-OHP levels helps clinicians differentiate between various intersex conditions and establish an accurate diagnosis of female pseudohermaphroditism caused by congenital adrenal hyperplasia.

Evaluating Hirsutism and Virilization in Females

In adolescent girls and adult women, the 17-OH Progesterone test is performed to investigate signs of hyperandrogenism, such as hirsutism (excessive male-pattern facial and body hair), severe treatment-resistant acne, androgenetic alopecia (male-pattern baldness), and virilization (deepening of the voice, increased muscle mass, and clitoromegaly). These clinical features can be caused by non-classic congenital adrenal hyperplasia (NCCAH), also known as late-onset CAH. Unlike the classic form, NCCAH does not present with adrenal insufficiency or salt-wasting in infancy but manifests during or after puberty due to a mild, partial deficiency of the 21-hydroxylase enzyme. Distinguishing NCCAH from other common endocrine disorders like Polycystic Ovary Syndrome (PCOS) is essential for appropriate clinical management.

Assessing Oligomenorrhea and Female Infertility

Reproductive endocrinologists frequently include the 17-OH Progesterone test in the diagnostic workup for women presenting with oligomenorrhea (infrequent menstrual periods), amenorrhea (absence of menstruation), or unexplained infertility. Chronic anovulation is a common consequence of the elevated adrenal androgens associated with partial 21-hydroxylase deficiency. By measuring baseline 17-OHP levels, clinicians can determine whether adrenal dysfunction is contributing to the patient’s reproductive challenges. If baseline levels are borderline, an ACTH stimulation test may be performed, where 17-OHP is measured before and after the administration of synthetic ACTH (cosyntropin) to unmask a partial enzymatic block.

Monitoring CAH Treatment and Adrenal Enzyme Activity

For pediatric and adult patients who have been diagnosed with congenital adrenal hyperplasia, the 17-OH Progesterone test is utilized as a vital monitoring tool to assess the adequacy of glucocorticoid replacement therapy. The goal of treatment in CAH is to provide sufficient exogenous glucocorticoids (such as hydrocortisone) to replace the deficient cortisol and to suppress the excess secretion of Adrenocorticotropic Hormone (ACTH) by the pituitary gland. By suppressing ACTH, the overproduction of 17-OHP and adrenal androgens is minimized. Regular monitoring of 17-OHP levels helps endocrinologists titrate medication dosages, ensuring a balance between adequate adrenal suppression and the avoidance of glucocorticoid toxicity (Cushingoid side effects and growth suppression in children).

What Does a 17-OH Progesterone Detect?

The 17-OH Progesterone test is highly sensitive and capable of detecting a wide range of physiological states, enzymatic deficiencies, and pathological conditions. Specifically, this diagnostic investigation detects and assists in the clinical evaluation of:

• Classic Salt-Wasting 21-Hydroxylase Deficiency: Characterized by extremely high concentrations of 17-OHP, severe cortisol deficiency, and aldosterone deficiency, leading to life-threatening salt-wasting crises in neonates.
• Classic Simple Virilizing 21-Hydroxylase Deficiency: Marked by significantly elevated 17-OHP levels and prenatal virilization in females, but with sufficient aldosterone production to prevent renal salt-wasting.
• Non-Classic (Late-Onset) Congenital Adrenal Hyperplasia: Detected by moderately elevated basal 17-OHP levels or a dramatic hyper-response during an ACTH stimulation test, presenting in late childhood or adulthood.
• Heterozygous Carriers of CYP21A2 Mutations: Individuals carrying a single mutated allele may exhibit mild, subclinical elevations in 17-OHP, particularly after ACTH stimulation.
• Adrenal Cortical Tumors: Both benign adrenal adenomas and malignant adrenal cortical carcinomas can autonomously secrete steroid hormones, including 17-OH progesterone, leading to elevated systemic levels.
• Ovarian Hyperthecosis: A condition characterized by luteinized stromal cells within the ovaries that can produce excess steroid precursors, including 17-OHP.
• Polycystic Ovary Syndrome (PCOS): While primarily an ovarian disorder, some patients with PCOS show mild elevations in 17-OHP due to generalized adrenal hyper-responsiveness.
• Pregnancy-Related Hormonal Elevations: Normal physiological elevation of 17-OHP produced by the corpus luteum and the placenta during a healthy pregnancy.
• Luteal Phase Elevation: Normal cyclical increases in 17-OHP levels during the second half of the menstrual cycle in menstruating females.
• Neonatal Stress Response: Transient elevations of 17-OHP in premature or critically ill infants due to immature adrenal enzyme systems and physiological stress.
• 11-Beta-Hydroxylase Deficiency (CAH Type 2): A less common form of CAH where 17-OHP levels may be mildly to moderately elevated due to upstream accumulation, though 11-deoxycortisol is the primary marker.
• 3-Beta-Hydroxysteroid Dehydrogenase Deficiency (CAH Type 3): A rare form of CAH that can cause elevations in 17-OHP along with other dehydroepiandrosterone (DHEA) precursors.
• Adrenal Insufficiency (Addison’s Disease): While primary adrenal insufficiency typically presents with low cortisol, evaluating the entire steroid pathway, including 17-OHP, helps localize the site of adrenal dysfunction.
• Hypopituitarism: Secondary adrenal insufficiency due to pituitary failure results in low ACTH levels, leading to low baseline levels of 17-OH progesterone.
• Exogenous Glucocorticoid Suppression: Detection of abnormally low 17-OHP levels in patients undergoing corticosteroid therapy, indicating suppression of the HPA axis.
• Precocious Puberty: Evaluation of early-onset secondary sexual characteristics in children to rule out adrenal-derived androgen excess.
• Delayed Puberty: Investigating potential enzymatic blocks or adrenal hypoplasia in adolescents presenting with delayed sexual maturation.
• Adrenarche Abnormalities: Differentiating premature adrenarche from mild forms of congenital adrenal hyperplasia in young children.
• Ovarian Tumors: Certain hormone-secreting ovarian neoplasms, such as granulosa-theca cell tumors, can secrete progesterone and its 17-hydroxy derivative.
• Testicular Tumors: Leydig cell tumors or adrenal rest tumors in the testes of males with poorly controlled CAH can produce elevated levels of 17-OHP.
• Therapeutic Compliance: Monitoring fluctuations in 17-OHP levels to assess patient adherence to prescribed daily glucocorticoid regimens.
• Enzymatic Block Severity: Assessing the quantitative level of 17-OHP to estimate the degree of residual 21-hydroxylase enzyme activity.
• HPA Axis Recovery: Monitoring the gradual return of endogenous adrenal steroidogenesis, including 17-OHP production, after the cessation of long-term steroid therapy.
• Ectopic ACTH Syndrome: Extremely high ACTH levels from non-pituitary tumors can overstimulate the adrenal cortex, resulting in elevated 17-OHP levels.
• Congenital Adrenal Hypoplasia: A rare genetic disorder resulting in underdevelopment of the adrenal glands, characterized by profoundly low levels of all adrenal steroids, including 17-OHP.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing accurate diagnostic insights with optimal efficiency. Due to the specialized nature of hormone assays, the 17-OH Progesterone test is performed using highly calibrated automated analyzers under strict quality control protocols. The typical turnaround time (TAT) for this investigation is 24 to 48 hours from the time of sample collection. However, this may vary slightly depending on the specific testing schedule of the reference laboratory and the geographic location of the collection center.

Patients can access their diagnostic reports seamlessly through Chughtai Lab’s advanced digital health ecosystem. Once the clinical pathologist verifies and signs off on the results, an automated SMS notification containing a secure download link is sent to the patient’s registered mobile number. Reports can be viewed, downloaded, and shared via the official Chughtai Lab mobile application (available on iOS and Android) or through the online patient portal on the Chughtai Lab website. Additionally, patients can obtain physical copies of their reports at any of the numerous Chughtai Lab collection centers located nationwide.

17-OH Progesterone Findings Overview

The interpretation of 17-OH Progesterone levels requires careful consideration of the patient’s age, biological sex, developmental stage, and, for females, menstrual status or pregnancy. The table below provides a general clinical overview of reference ranges and potential findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Newborns (Full-term, <3 days)	< 2.0 ng/mL (highly variable in first 48 hours)	Elevated: Suggestive of Classic Congenital Adrenal Hyperplasia (CAH).
Newborns (Pre-term)	< 5.0 ng/mL (elevated due to adrenal immaturity)	Significantly Elevated: Requires serial monitoring to differentiate from transient neonatal stress.
Infants (1 to 12 months)	< 1.0 ng/mL	Elevated: Indicates potential 21-hydroxylase deficiency or other enzymatic blocks.
Adult Males	0.3 – 2.0 ng/mL	Elevated: Adrenal tumors, late-onset CAH, or testicular adrenal rest tumors.
Adult Females (Follicular Phase)	0.1 – 0.8 ng/mL	Elevated: Non-classic CAH (NCCAH), adrenal hyperplasia, or ovarian hyperthecosis.
Adult Females (Luteal Phase)	0.6 – 2.3 ng/mL	Significantly Elevated (> 5.0 ng/mL): Suggests partial 21-hydroxylase deficiency or adrenal pathology.
Adult Females (Postmenopausal)	< 0.5 ng/mL	Elevated: Adrenal cortical adenoma, carcinoma, or late-onset CAH.
Pregnant Females (Third Trimester)	2.0 – 12.0 ng/mL (physiologically elevated)	Abnormally High: Requires clinical correlation with maternal and fetal health status.
ACTH Stimulation Test (Post-Stimulation)	< 3.0 ng/mL (normal response)	> 10.0 ng/mL: Diagnostic of Non-Classic CAH; > 100 ng/mL: Diagnostic of Classic CAH.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for 17-OH Progesterone?

• Experienced Healthcare Professionals: Chughtai Lab employs highly qualified clinical pathologists, biochemists, and laboratory technologists who specialize in endocrine assays and complex hormone analysis.
• Patient-Focused Care: Every step of the diagnostic journey, from sample collection to report delivery, is designed to prioritize patient comfort, safety, and confidentiality.
• Quality Diagnostic Services: The laboratory operates under strict internal quality control measures and participates in international external quality assurance programs to ensure the highest accuracy.
• Professional Reporting: Reports are presented in a clear, comprehensive, and standardized format, featuring detailed reference ranges tailored to age, sex, and physiological status.
• Modern Diagnostic Approach: Chughtai Lab utilizes state-of-the-art automated immunoassay platforms and advanced laboratory information management systems (LIMS) to minimize human error.
• Comfortable Environment: All collection centers are designed to provide a clean, hygienic, and welcoming atmosphere for patients of all ages, including pediatric patients.
• Convenient Location: With an extensive network of hundreds of collection centers across Pakistan, patients can easily find a Chughtai Lab facility near their home or workplace.
• Commitment to Accurate Diagnosis: Chughtai Lab’s dedication to clinical excellence ensures that physicians receive reliable diagnostic data to make informed treatment decisions.